John Nemunaitis

Impact of the Taylor Cancer Research Center (TCRC) and Tempus AI TIME Partnership on clinical trial start-up and accrual.

John Nemunaitis, Nadine Nemunaitis, Renee Sattler, John Dellostritto et autres

1565 Background: TCRC is a nonprofit oncology community practice serving patients in Northwestern Ohio. TCRC's partnership with the Tempus AI TIME program leverages proprietary software and nursing teams to support patient matching across a portfolio of industry-sponsored clinical trials. Trials may be …

us (code pays fourni par la source)

In Vivo Assessment of dbDNA GNE wt /bi‐shRNA‐GNE M743T Lipoplex for GNE Myopathy: Improved Potency and Safety

Christopher M. Jay, Fabienne Kerneis, D.R. Rao, Alexander Nemunaitis et autres

ABSTRACT GNE myopathy is an autosomal recessive disease, associated with skeletal muscle deterioration, which afflicts young adults. GNE plays a pivotal role in sialic acid production. Sialic acid acts as a buffer against reactive oxygen species generated during muscle contraction. Increased oxidative …

us (code pays fourni par la source)

Preclinical assessment of GNEwt/bi-shRNA-GNEM743T lipoplex product development for GNE myopathy

Fabienne Kerneis, Christopher M Jay, Donald Rao, Jeremy Winchester et autres

GNE myopathy is a heredity disease of unmet medical need associated with progressive skeletal muscle wasting, atrophy and weakness caused by mutations in the GNE gene. GNE plays a pivotal role in sialic acid production. Sialic acid is a critical part of …

Preclinical assessment of GNEwt/bi-shRNA-GNEM743T lipoplex product development for GNE myopathy

Fabienne Kerneis, Christopher M Jay, Donald Rao, Jeremy Winchester et autres

GNE myopathy is a heredity disease of unmet medical need associated with progressive skeletal muscle wasting, atrophy and weakness caused by mutations in the GNE gene. GNE plays a pivotal role in sialic acid production. Sialic acid is a critical part of …

Preclinical assessment of GNE wt /bi-shRNA-GNE M743T lipoplex product development for GNE myopathy

Fabienne Kerneis, Christopher M. Jay, Donald D. Rao, Jeremy Winchester et autres

Aims GNE myopathy is a heredity disease of unmet medical need associated with progressive skeletal muscle wasting, atrophy and weakness caused by mutations in the GNE gene. GNE plays a pivotal role in sialic acid production. Sialic acid is a critical part …

us, gb, fr (code pays fourni par la source)

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer

Robert L. Coleman, Rodney P. Rocconi, Bradley J. Monk, Adam Walter et autres

PURPOSE Frontline ovarian cancer treatment protocols involving bevacizumab, poly (ADP-ribose) polymerase inhibitors, and PD-1/PD-L1 inhibitors have failed to improve overall survival (OS) in patients with homologous recombination–proficient (HRP) tumors. To determine mechanistic mutation signatures associated with OS advantage, we constructed a whole-exome …

us (code pays fourni par la source)

supplementary table 1 from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA

Peter M. Anderson, Maurizio Ghisoli, Brian D. Crompton, Kelly Klega et autres

supplementary table

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Nitin Jain, Catherine C. Coombs, James D’Olimpio, Nirav N. Shah et autres

Abstract Background Covalent and non-covalent Bruton’s tyrosine kinase inhibitors (c/ncBTKis) are approved for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and B-cell non-Hodgkin lymphoma (NHL), but their long-term efficacies are limited due to the off-target toxicities and the acquired …

us, gb (code pays fourni par la source)

1029eTiP A phase I/II open-label study of NDI-219216, a WRN inhibitor, in patients with advanced solid tumors with or without microsatellite instability /deficient mismatch repair

John Nemunaitis, A. Scheuber, Timothy E. Bael, Benedito A. Carneiro et autres

us, es, ie, fr, au, pt (code pays fourni par la source)

Impact of large language models on trial-to-patient matching efficiency.

Sarah Salzman, Gabriel Altay, Kunal Nagpal, Vivek Shetye et autres

e13600 Background: Timely and accurate clinical trial matching is critical to providing additional treatment options for patients, especially when standard-of-care treatments are limited. However, trial matching is time-consuming, leading to missed patient opportunities and delays in trial enrollment. The Tempus AI TIME …

us (code pays fourni par la source)

Molecular residual disease (MRD) in solid tumors.

Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral et autres

TPS3186 Background: Pragmatically designed clinical studies facilitate rapid accrual of representative populations by aligning research with routine care and enabling study execution in community practice settings. In addition, the implementation of technologies to streamline patient ascertainment and data collection further reduce site …

us (code pays fourni par la source)

Clinical characterization and therapeutic targeting of fusion genes in oncology

Susan Morand, Lauren Elizabeth Rager, Daniel J. Craig, Alexander Nemunaitis et autres

Gene fusions represent important oncogenic driver mutations resulting in aberrant cellular signaling. In up to 17% of all solid tumors at least one gene fusion can be identified. Precision therapy targeting fusion gene signaling has demonstrated effective clinical benefit. Advancements in clinically …

us (code pays fourni par la source)